Combination of psycho- and pharmacotherapy as a modern method of treatment of Alzheimer's disease.
KeywordsAlzheimer's disease, pharmacotherapy, psychotherapy, communication
Introduction: Alzheimer's disease is a degenerative disease of the brain, caused by the deposition of beta-amyloid and tau protein. It is characterized by progressive memory and behavior disorders which, over time, completely prevent the patient from functioning properly in everyday life, performing work and disrupting social contacts. Communication problems arise and patients forget more and more words. Unfortunately, we are not able to completely stop the progression of this disease, but we can only delay its development. To delay the progression of the disease, pharmacotherapy includes acetylcholinesterase inhibitors and NMDA receptor antagonists.
Matherials and methods: This article, based on a PubMed review of available research, examines the impact of rivastigmine, donepezil, memantine and psychotherapy on delaying disease progression.
Results: A number of studies have investigated the effect of 6-12 milligrams of rivastigmine, 10 milligrams of donepezil and 20 milligrams of memantine on patients' ability to communicate. The results were checked using the MMSE, ADAS or SIB scales and interviews conducted regularly by clinicians. In addition, patients were subjected to various forms of psychotherapy, including reminiscence therapy and cognitive therapy. All groups experienced significantly less deterioration in their functional stage of disease compared to the placebo groups.
Conclusions: The best results in the treatment of Alzheimer's disease can be obtained by combining pharmacological therapy with non-pharmacological effects. Thanks to this form of treatment, the progression of the disease is delayed, and patients retain their communication abilities for longer.
Szczeklik A, Gajewski P, Interna Szczeklika 2017, Medycyna Praktyczna, Kraków 2017.
Parnowski T, Choroba Alzheimera, PZWL, Warszawa 2020.
Potocka-Pirosz K, Zaburzenia mowy we wczesnej fazie choroby Alzheimera, Wydawnictwa Uniwersytetu Warszawskiego, Warszawa 2019.
Grossberg G, Choroba Alzheimera. Najnowsze strategie diagnostyczne i terapeutyczne, Medisfera, Warszawa 2011.
Tang-Wai DF, Graham NL. Assessment of language function in dementia. Geriatr Aging. 2008; 11: 103–110.
Farlow MR, Cummings JL, Olin JT, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2010; 25(4): 347–352.
Cummings J, Jones R, Wilkinson D, et al. Effect of donepezil on cognition in severe Alzheimer’s disease: a pooled data analysis. J Alzheimers Dis. 2010; 21(3): 843–851.
Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-BEST Study (benefit and efficacy in severely de-mented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-146
Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007; 53: 699-723.
Degerman Gunnarsson M, Kilander L, Basun H, Lannfelt L. Reduction of phosphorylated tau during memantine treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 24: 247-252.
Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004; 38: 1389-1394.
Yao C, Raoufinia A, Gold M, Nye JS, Ramael S, Padmanabhan M. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005; 45: 519-528.
Shua-Haim J, Smith J, Picard F, Sedek G, Athalye S, Pommier F. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin Drug Investig 2008; 28: 361-374.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-324.
Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22: 209-221.
Długosz-Mazur E, Niefarmakologiczne metody postępowania u chorych z otępieniem., Medycyna Ogólna i Nauki o Zdrowiu, 2013, Tom 19, Nr 4, 458–462.
Kiejna A, Standardy leczenia otępień. Psychogeriatria Polska, 2008; 5(2): 59-94.
Cameron DA, Psychiatria crash course, Elsevier Urban&Partner, Wrocław 2009.
How to Cite
Copyright (c) 2023 Magdalena Próchnicka, Dominika Nowak, Michał Siwek, Adrian Giermasiński, Weronika Tuszyńska, Adam Zarzycki, Bartosz Skorupski, Mateusz Komisarczuk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 132
Number of citations: 0